全文获取类型
收费全文 | 2316篇 |
免费 | 118篇 |
国内免费 | 30篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 116篇 |
妇产科学 | 56篇 |
基础医学 | 205篇 |
口腔科学 | 41篇 |
临床医学 | 130篇 |
内科学 | 321篇 |
皮肤病学 | 48篇 |
神经病学 | 114篇 |
特种医学 | 356篇 |
外科学 | 413篇 |
综合类 | 156篇 |
预防医学 | 104篇 |
眼科学 | 121篇 |
药学 | 158篇 |
1篇 | |
中国医学 | 9篇 |
肿瘤学 | 105篇 |
出版年
2023年 | 17篇 |
2022年 | 13篇 |
2021年 | 46篇 |
2020年 | 26篇 |
2019年 | 22篇 |
2018年 | 48篇 |
2017年 | 31篇 |
2016年 | 36篇 |
2015年 | 53篇 |
2014年 | 75篇 |
2013年 | 88篇 |
2012年 | 123篇 |
2011年 | 129篇 |
2010年 | 84篇 |
2009年 | 71篇 |
2008年 | 122篇 |
2007年 | 136篇 |
2006年 | 90篇 |
2005年 | 88篇 |
2004年 | 75篇 |
2003年 | 83篇 |
2002年 | 70篇 |
2001年 | 60篇 |
2000年 | 54篇 |
1999年 | 51篇 |
1998年 | 54篇 |
1997年 | 46篇 |
1996年 | 45篇 |
1995年 | 31篇 |
1994年 | 25篇 |
1993年 | 29篇 |
1992年 | 26篇 |
1991年 | 38篇 |
1990年 | 22篇 |
1989年 | 64篇 |
1988年 | 48篇 |
1987年 | 38篇 |
1986年 | 45篇 |
1985年 | 36篇 |
1984年 | 18篇 |
1983年 | 20篇 |
1982年 | 28篇 |
1981年 | 16篇 |
1980年 | 23篇 |
1979年 | 15篇 |
1978年 | 20篇 |
1977年 | 18篇 |
1976年 | 13篇 |
1975年 | 9篇 |
1973年 | 7篇 |
排序方式: 共有2464条查询结果,搜索用时 437 毫秒
51.
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. 总被引:10,自引:0,他引:10
S E Jones J Erban B Overmoyer G T Budd L Hutchins E Lower L Laufman S Sundaram W J Urba K I Pritchard R Mennel D Richards S Olsen M L Meyers P M Ravdin 《Journal of clinical oncology》2005,23(24):5542-5551
PURPOSE: This randomized, controlled, multicenter, open-label, phase III study compared docetaxel versus paclitaxel in patients with advanced breast cancer that had progressed after an anthracycline-containing chemotherapy regimen. PATIENTS AND METHODS: Patients (n = 449) were randomly assigned to receive either docetaxel 100 mg/m2 (n = 225) or paclitaxel 175 mg/m2 (n = 224) on day 1, every 21 days until tumor progression, unacceptable toxicity, or withdrawal of consent. RESULTS: In the intent-to-treat population, both the median overall survival (OS, 15.4 v 12.7 months; hazard ratio [HR], 1.41; 95% CI, 1.15 to 1.73; P = .03) and the median time to progression (TTP, 5.7 months v 3.6 months; HR, 1.64; 95% CI, 1.33 to 2.02; P < .0001) for docetaxel were significantly longer than for paclitaxel, and the overall response rate (ORR, 32% v 25%; P = .10) was higher for docetaxel. These results were confirmed by multivariate analyses. The incidence of treatment-related hematologic and nonhematologic toxicities was greater for docetaxel than for paclitaxel; however, quality-of-life scores were not statistically different between treatment groups over time. CONCLUSION: Docetaxel was superior to paclitaxel in terms of OS and TTP. ORR was higher for docetaxel. Hematologic and nonhematologic toxicities occurred more frequently in the docetaxel group. The global quality-of-life scores were similar for both agents over time. 相似文献
52.
53.
54.
55.
56.
Tessa S. Cook Anand Sundaram William W. Boonn Woojin Kim 《Journal of digital imaging》2013,26(4):663-667
The need for tools to monitor imaging-related radiation has grown dramatically in recent years. RADIANCE, a freely available open-source dose-monitoring tool, was developed in response to the need for an informatics solution in this realm. A number of open-source as well as commercial solutions have since been developed to enable radiology practices to monitor radiation dose parameters for modalities ranging from computed tomography to radiography to fluoroscopy. However, it is not sufficient to simply collect this data; it is equally important to be able to review it in the appropriate context. Most of the currently available dose-monitoring solutions have some type of reporting capability, such as a real-time dashboard or a static report. Previous versions of RADIANCE have included a real-time dashboard with pre-set screens that plot effective dose estimates according to different criteria, as well as monthly scorecards to summarize dose estimates for individuals within a radiology practice. In this work, we present the RADIANCE toolkit, a customizable reporting solution that allows users to generate reports of interest to them, summarizing a variety of metrics that can be grouped according to useful parameters. The output of the toolkit can be used for real-time dose monitoring or scheduled reporting, such as to a quality assurance committee. Making dose parameter data more accessible and more meaningful to the user promotes dose reduction efforts such as regular protocol review and optimization, and ultimately improves patient care by decreasing unnecessary radiation exposure. 相似文献
57.
58.
59.
Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) can rarely cause alternate-sided homonymous hemianopia due to stroke-like episodes involving the occipital lobes, as reported in three previously published cases. The authors report an interesting case of a 16-year-old presenting with myoclonic epilepsy due to MELAS with the rare ND3 mitochondrial mutation T10191C, with recurrent alternate-sided homonymous hemianopia. Visual field and corresponding magnetic resonance imaging (MRI) findings are presented. To the authors’ knowledge, this is the first report of recurrent alternate-sided homonymous hemianopia in MELAS with documented visual field and MRI findings with resolution between each episode. 相似文献
60.
继续医学教育的目的是通过向医生提供最新的医学知识和技能,使医生在其整个职业生涯中,一直保持较高的医疗水平.但目前还没有充足的证据能证明继续医学教育活动的有效性,以及在继续医学教育活动中哪些教育方法和技术能最有效地传播和记忆医学知识.为了全面、系统地评估继续医学教育活动的有效性,以及了解不同的教育手段对医生知识、态度、技能、临床表现和临床效果的作用.美国约翰·霍普金斯大学医学院、美国医疗保健研究与质量管理署和美国胸科医师学会的专家共同进行了一项系统回顾性研究. 相似文献